The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2020

Filed:

Feb. 23, 2015
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Marian Gindy, North Wales, PA (US);

Danilo R. Casimiro, Harleysville, PA (US);

Andrew Bett, Lansdale, PA (US);

Jan H. Ter Meulen, Mercer Island, WA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 39/12 (2006.01); A61K 9/50 (2006.01); A61K 31/451 (2006.01); A61K 31/80 (2006.01); A61K 39/29 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61P 31/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 9/5015 (2013.01); A61K 9/5031 (2013.01); A61K 31/451 (2013.01); A61K 31/80 (2013.01); A61K 39/12 (2013.01); A61K 39/292 (2013.01); C12N 7/00 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61P 31/00 (2018.01); C12N 2730/10134 (2013.01); C12N 2730/10171 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24171 (2013.01); Y02A 50/386 (2018.01); Y02A 50/412 (2018.01);
Abstract

The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.


Find Patent Forward Citations

Loading…